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Abstract
The objective of interstitial laser coagulation (ILC) of
benign prostatic enlargement is to achieve a marked vol-
ume reduction and to decrease bladder outlet obstruc-
tion and lower urinary tract symptoms with minimal
morbidity. Coagulation necrosis is generated well inside
the adenoma by means of specifically designed laser
applicators combined with either a Nd:YAG laser or a
diode laser. Because the laser applicators can be in-
serted as deeply and as often as necessary, it is possible
to coagulate any amount of tissue at any desired location
while preserving adjacent structures such as the urethra.
Postprocedural, the intraprostatic lesions result in sec-
ondary atrophy and regression of the prostate lobes,
rather than sloughing of necrotic tissue. Several single-
armed and randomized studies indicated the effective-
ness of interstitial laser coagulation of BPH-syndrome.
Marked improvements in AUA score, peak flow rate,
residual urine volume and prostate volume were re-
ported. Pressure-flow studies demonstrated a sufficient
decrease of the intravesical/detrusor pressure, urethral
opening pressure and urethral resistance. Long-term re-
sults demonstrating sustained success for up to 3 years
were reported on a series of 394 patients. ILC is suitable
to debulk even large prostates and to treat highly ob-
structive patients. Therefore, ILC can be seen as a true
alternative to TURP with certain advantages, such as
almost no serious morbidity and with certain disadvan-
tages, such as the need for postoperative catheterization.
However, ILC can be done under local anesthesia and
does not require hospitalization.
Introduction
Interstitial ‘laserthermia’ employing low-power laser
radiation was first mentioned by Bown [1] in 1983. In
1984, interstitially applied laser radiation of lower power
was experimentally tested for nonthermal photochemical
effects in photodynamic therapy (PDT) [2]. Both concepts
of interstitial laser therapy, the thermal and nonthermal
approaches, were exclusively used to treat solid malignant
tumors [3]. In the prostate, initial studies on interstitial
laser therapy also focused on cancer treatment. Interstitial
PDT experiments on transplanted prostate cancer cells
were done as early as 1984 and 1985 [2, 4]. In 1988, Lit-
trup et al. [5] and McNicholas et al. [6] performed animal
experiments employing bare fibers to generate thermal
lesions. The latter authors, who irradiated the prostate for
treatment times from 200 to 1,500 s with 1–2 W, found
lesions of up to 1 cm in diameter [7, 8]. In 1992, the first
patients with localized prostate cancer were treated before
radical prostatectomy using the bare fiber technique
[8, 9].
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Fig. 1. ITT light guide, quartz glass fiber 600 Ìm, applicator 1.9 mm
in diameter, 2 cm in length, 90°-cone shape radiation pattern (in air
or water).
Fig. 2. Diffusor-Tip laser fiber 600 Ìm, applicator 2 mm in diame-
ter, 2 cm in length, homogenous diffuse radiation over 1 cm.
Interstitial laser coagulation (ILC) of benign prostatic
hyperplasia (BPH) achieved with fibers specifically de-
signed for this purpose was first mentioned by Hofstetter
[10] in 1991, with the basic experiments and initial clini-
cal results published by Muschter et al. [11] in 1992. Since
then, several variations and technical and procedural
developments have been introduced and tested in clinical
trials [12–17].
The objective of ILC of BPH is to achieve a marked
volume reduction, and to decrease urethral obstruction
and both obstructive and irritative symptoms. Coagula-
tion necrosis is generated well inside the adenoma, rather
than at its urethral surface. Because the applicator can be
inserted as deeply and as often as necessary, it is possible
to coagulate any amount of tissue at any desired location.
Postprocedural, the intraprostatic lesions result in sec-
ondary atrophy and regression of the prostate lobes, rath-
er than sloughing of necrotic tissue [13, 16, 18–21].
Material and Methods
Because of their relatively deep penetration in water, efficient
volumetric heating permitting necrotic temperatures deep into tis-
sues, and the ability to be delivered with flexible optical fibers,
Nd:YAG lasers (1,064 nm) or diode lasers (approximately 800–
1,000 nm) are used for interstitial laser coagulation [11, 16, 18, 21–
27]. Recent experiments, however, demonstrated that the Ho:YAG
laser (2,120 nm) is also suitable to generate interstitial lesions. This
laser, however, does not generate a homogenous coagulation zone,
but a central cavity with adjacent charring and peripheral coagula-
tion [28].
Fibers employed for ILC must emit laser radiation at a relatively
low power density. One type of fiber emits the laser radiation circum-
ferentially forward directed with a ring/cone-shaped beam profile
(e.g. ITT light guideTM, Dornier, Germering, Germany; fig. 1) [29], or
Interstitial Laser Fiber, Baasel Lasertechnik, Starnberg, Germany;
fig. 2). Another type of fiber is a cylindrical diffuser tip emitting in all
directions from the whole length of the applicator (e.g. Diffusor-
TipTM, Indigo, Cincinnati, Ohio, USA; fig. 3). Other types of intersti-
tial application systems or bare fibers were predominantly used
experimentally [16–19, 23, 30, 31]. The optimal radiation parame-
ters vary for different laser wavelength and applicator combinations
[11, 16, 23, 25, 28, 30, 31]. Using constant laser power in the 5–7 W
range, the maximal coagulation volume can be expected within
approximately 10 min irradiation time without the risk of carboniza-
tion [11, 21, 22, 32]. A more rapid heating by using higher laser pow-
er will reduce irradiation time, but increases the risk of carbonization
[22, 33]. For short irradiation times, however, high powers are tolera-
ble. In this type of laser energy application, irradiation starts with a
relatively high power to rapidly heat the tissue and coagulate the
blood vessels (e.g. 20 W for 30 s or 50 W for 10 s) [14, 21, 22, 34]. The
laser power is then reduced repeatedly or continuously to maintain
the temperature in the center of the lesion at a high level just below
the carbonization threshold, and to allow further lesion growth. On-
line temperature monitoring by use of a thermocouple integrated into
the application fiber allows further optimization by use of a feedback
control [15, 35, 36]. Optical feedback systems can also detect any
carbonization. If this occurs at the applicator, laser irradiation is
automatically terminated. This prevents overheating and therefore
potential thermal fiber damage.
ILC can be performed with local (e.g. periprostatic block) [34],
regional (e.g. spinal), or systemic (e.g. analgosedation) anesthetic.
The procedure is suitable to treat outpatients.
ILC can be done using the transurethral approach, in which the
laser fiber is introduced from a cystoscope within the urethra [12, 13,
21, 33, 36–41], or the percutaneous (perineal) approach, in which the
laser applicator is introduced through hollow needles in the peri-
neum, guided by transrectal ultrasound [13, 21, 33, 42, 43].
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Fig. 3. Interstitial laser applicator, low-OH quartz glass fiber
600 Ìm, applicator 1.8 mm in diameter, 2 cm in length, 160°-cone
shape radiation pattern (in air or water).
Fig. 4. ILC treatment of the right apex.
The commonly used transurethral ILC requires a cystoscope with
a working channel of 5 to 6 French. An ideal instrument has a small
separate working channel that ends at the level of the telescope for
optimal stabilization of the fiber during puncture.
The total number of fiber placements is dictated by the total pros-
tate volume and configuration. A general guideline would be one to
two applicator placements for each estimated 5 to 10 cm3 of prostate
tissue or approximately one to three placements per lobe per each cm
of the prostatic urethra length. Individual placements of the laser
fiber are spaced by about 0.5 to 1 cm and/or are performed at differ-
ent angles and depths. In general, the sites for fiber placement are
chosen where the bulk of hyperplastic tissue is found. The most api-
cal punctures are performed in the prostatic urethra just proximal of
the external sphincter (fig. 4) so that no apical tissue goes untreated.
When punctures of the median lobe are done, the fiber is always
advanced in the direction of the bladder to prevent subtrigonal coag-
ulation. Fiber penetration of the capsule is almost impossible because
of the limited penetration angle and depth achievable. In addition,
the highly vascular nature of the prostate capsule acts as a heat sink
and prevents potential coagulation of the capsule itself and adjacent
structures, if the fiber is placed close. This was proven by magnetic
resonance imaging studies performed during and after ILC [44–46]
and by pathological studies when ILC was done before open prosta-
tectomy [35]. However, one should avoid advancing the applicator
dorsally because this prevents any theoretical risk of affecting the
neurovascular bundles and rectum and yet there is little or no BPH
tissue to treat.
Clinical Results
Several studies indicated the effectiveness of intersti-
tial laser coagulation of BPH regarding all of the three
characteristics of the disease: symptoms, obstruction and
enlargement. All studies reported marked improvements
in AUA score, peak flow rate (table 1), residual urine vol-
ume and prostate volume (table 2) [12–14, 16, 19, 33, 36–
38, 40–43, 47–49]. The latter was not only demonstrated
by measurements based on transrectal ultrasound, but
also in studies using magnetic resonance imaging for vol-
ume measurements during follow-up [37, 45]. Analysis of
possible factors predicting final success or failure clearly
demonstrated the effect of the learning curve [50] and a
correlation with the number of punctures per prostate vol-
ume. If less than one application per 5–7 ml of prostate
volume was done, the results were less favorable [37, 42,
51, 52].
Urodynamic parameters were also measured before
and after ILC treatment [42, 43, 53, 54]. Pressure-flow
studies demonstrated a sufficient decrease of the intrave-
sical/detrusor pressure, urethral opening pressure and the
urethral resistance. The detrusor pressure at Qmax. im-
proved from 77.4 to 57.1 cm H2O [53] in one and from 59
to 48 cm H2O [43] in another study. The authors found
this parameter ‘normal’ in 48% of their group of high-risk
patients after ILC for severely obstructive BPH [42, 54].
Long-term results demonstrating sustained success on
a series of 394 patients treated from 1991 through to 1994
were reported in 1997 (table 3) [34].
Prospective and randomized studies were also per-
formed to compare the results achieved with ILC to those
of other laser techniques [43, 55] and primarily transure-
thral resection of the prostate (TURP) [56–62]. In one
series [56–58] 97 patients with severely symptomatic
BPH were treated. 48 patients received ILC using stan-
dardized instrumentation (Nd:YAG laser, ITT light gui-
Arai et al. [37]
Arai et al. [37]
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Table 1. Symptom score and urinary peak
flow changes after ILC: literature review Author n Follow-
up
months
AUA score
preop postop
Peak flow, ml/s
preop postop
70 6 18.9 7.7 6.7 10.0
de la Rosette et al. [36] 25 3 20.6 6.9 9.1 20.3
Henkel et al. [42] 35 12 21 8 5.3 10.0
Horninger et al. [43] 12 12 29 6 8.3 16.9
Martov and Kilchukov [38] 25 6 19.9 13.5 8.7 13.5
McNicholas and Alsudani [19] 36 12 22 7 9.4 14.6
Muschter and Hofstetter [13, 33] 239 12 25.4 6.1 7.7 17.8
Muschter et al. [47] 48 12 31.0 2.3 9.4 19.7
Muschter et al. [12] 112 6 20.9 7.9 8.0 14.2
Muschter et al. [14] 42 3 22.1 4.2 8.2 24.9
Orovan and Whelan [40] 16 3 16.3 5.8 8.8 11.9
Roggan et al. [16] 27 2 14 5 8.0 13.0
Schettini et al. [41] 20 3 22.6 9.2 7.9 15.0
Whelan [48] 112 6 18.2 8.2 10.4 17.0
Zhenghua and Ciling [49]* 78 3 22.5 8.5 9.8 16.5
* ILC + bladder neck incision.
Table 2. Prostate volume changes after ILC: literature review
Author Prostate volume, ml
preop postop
% volume
decrease
37.1 31.6 14.8
Henkel et al. [42] 67 43 35.8
Horninger et al. [43] 57.0 52.3 8.3
Martov and Kilchukov [38] 53.8 42.1 21.8
Muschter and Hofstetter [13, 33] 47.4 29.1 38.6
Muschter et al. [47] 47.1 27.5 41.6
Roggan et al. [16] 49 36 26.5
Schettini et al. [41] 66.6 49.0 26.4
Whelan [48] n.d. n.d. 26.1
Zhenghua and Ciling [49] 40 28 30.0
n.d. = No data.
* ILC + bladder neck incision.
Table 3. Long-term results of ILC in 394 patients treated in 1991–
1994.
Preop 1 year
postop
2 years
postop
3 years
postop
AUA score 24.2 6.3 6.8 7.9
Peak flow, ml/s 7.9 17.2 15.7 15.2
deTM), application technique (transurethral application
with an ‘integrated’ cystoscope), and laser parameters
(power stepwise reduced from 20 to 7 W, 3 min total irra-
diation time per fiber placement) and were compared pro-
spectively with 49 TURP patients. Within 12 months
AUA score improved from 31.0 to 2.3 points (TURP:
31.1 to 3.5 points), life quality index from 4.7 to 0.6
points (TURP: 4.7 to 1.3 points), peak flow rate from 9.4
to 19.7 ml/s (TURP: 8.9–25.6 ml/s), residual urine vol-
ume from 128 to 17 ml (TURP: 167–7 ml), and prostate
volumes from 47.1 to 27.5 ml (TURP: 40.2–21.2 ml) on
average. Four ILC patients were noted as treatment fail-
ures and received retreatment by transurethral resection.
In a prospective randomized multicenter study a 10-W
diode laser system was used [59–61]. Six months follow-
up in 166 patients [60] showed marked improvements in
both groups, TURP, however, was significantly better
(AUA score improving from 22.4 to 6.5 vs. ILC from 21.5
to 9.7; peak flow rate improving from 8.3 to 20.3 ml/s vs.
ILC from 8.3 to 14.0 ml/s). Another prospective random-
ized study using the 10-W diode laser on 44 patients (20
ILK, 24 TURP) with a follow-up of 6 months demon-
strated similar results [62]. The AUA score improved
from 23 to 10.8 (TURP: 22.5–8.6) and the peak flow rate
from 7.5 to 11.6 ml/s (TURP: 8.8–18.9 ml/s).
Blood transfusion
Arai et al. [37]
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Side Effects – Morbidity
After ILC, a temporary increase of obstruction which
can go along with urinary retention and temporary irrita-
tive symptoms such as urgency normally occurs. The lat-
ter was observed in approximately 5–15% patients [12–
14, 16, 19, 36–43, 47–52, 55–62]. Postoperative catheter-
ization, either transurethral or suprapubic, was required
for an average of up to 18.3 days, but was much shorter in
most studies with the catheter removed in more than 70%
of patients within ten days [12–14, 16, 19, 36–43, 47–52,
55–62]. No study reported any occurrence of impotence
or sustained incontinence [12–14, 16, 19, 36–43, 47–52,
55–62]. Retrograde ejaculation occurred occasionally,
with reported rates varying from 0 to 11.9%, very likely
depending on the aggressiveness of treatment in total and
of the bladder neck in particular [12–14, 37]. Urethral
strictures or bladder neck strictures were reported in a fre-
quency of approximately 5% for the first series of pa-
tients, but were not observed in subsequent series. Most
complications, in particular the more serious ones, be-
came less frequent or absent with increasing experience
(table 4). Uncomplicated urinary tract infections oc-
curred relatively frequent [12–14] and were probably
related to postoperative catheterization. The need for
repeated BPH treatment because of treatment failure
occurred at varying rates between 0 and 15.4% (table 5)
[12–14, 16, 17, 19, 33, 36–43, 47, 49] and 3.1% in the
second and third year [34].
Discussion
An interpretation of the results of the different studies
is interesting because it shows clearly the influence of the
learning curve of both the operating urologist and the
laser manufacturers on the clinical outcome, but also the
role of patient selection. While the improvement of symp-
toms is quite in the same range in the different studies and
comparable to TURP in randomized studies, the im-
provement of objective parameters shows a wider varia-
tion.
In some studies, very negative selected patients were
treated. Henkel et al. [42, 54] included only severely
obstructed high-risk patients not suitable for TURP, a
high percentage of them being in urinary retention. Hor-
ninger et al. [43] treated only patients with prostate vol-
umes of more than 50 ml.
For effective desobstruction, a large volume needs to
be coagulated. As stated above (see results chapter), clini-
cal results were better if a higher number of punctures per
Table 4. ILC complications: influence of treatment parameters and
experience (percent values)
Muschter and
Hofstetter
[13, 33]
(n = 239)
Muschter
et al. [12]
(n = 112)
Muschter
et al. [14]
(n = 42)
0.5 0 0
TUR syndrome 0 0 0
Clot retention 2 0 0
Incontinence 0 0 0
Bladder neck stricture 1.7 0 0
Urethral stricture 5.4 0 0
Epididymitis 1.5 0 0
Erectile dysfunction 0 0 0
Retrograde ejuaculation 6.7 3 11.9
Irritative symptoms 12.6 11 12.2
Urinary tract infection 35 27 16.5
Table 5. ILC failure rates: literature review
Author n Follow-
up
months
Retherapy
n %
70 6 5 7.1
de la Rosette et al. [36] 25 3 0 0
Handke et al. [17] 13 2 2 15.4
Henkel et al. [42] 35 12 3 8.6
Horninger et al. [43] 12 12 0 0
Martov and Kilchukov [38] 25 6 0 0
McNicholas and Alsudani [19] 36 12 0 0
Meagher [39] 36 n.d. 3 8.3
Muschter and Hofstetter [13, 33] 239 12 23 9.6
Muschter et al. [47] 48 12 4 8.3
Muschter et al. [12] 112 6 3 2.7
Muschter et al. [14] 42 3 5 11.9
Orovan and Whelan [40] 16 3 0 0
Roggan et al. [16] 27 6 1 4
Schettini et al. [41] 20 3 1 5
Zhenghua and Ciling [49]* 78 3 0 0
n.d. = No data.
* ILC + bladder neck incision.
volume were performed [37, 42, 43, 50]. This is a possible
explanation for the contrast in peak flow improvements
found with ILC in the randomized studies, when a 20-W
Nd:YAG laser or a 10-W diode laser was used. Whitfield
[59, 60] and de la Rosette et al. [61] performed only an
average of 6.7 punctures in an average 56 ml prostate.
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Fig. 5. Clinical outcomes of prospective nonrandomized and ran-
domized multicenter studies using 830-nm diode laser systems.
a Urinary peak flow rate. b Residual urine volume. c AUA score.
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Another reason for the contrasting results is probably
the learning curve. When Muschter and coworkers [56–
58] performed their prospective comparison to TURP,
they had already treated more than 400 patients [13, 33,
34]. In their first series of 239 patients, Muschter and
Hofstetter [13, 33, 50] demonstrated in a multivariate
analysis a correlation of the clinical improvements and
the number of cases performed previously.
The effect of improved technology is the third possible
reason. When comparing randomized and nonrandom-
ized multicenter studies published by Muschter et al. [12],
Whitfield [59, 60] and de la Rosette et al. [36, 61], all
employing an 830-nm diode laser, a clear improvement of
the clinical outcome regarding the peak flow rate and
residual volume is seen when in a consecutive series a
temperature-feedback controlled 20-W model was used
instead of the 10-W model employed in the first uncon-
trolled and randomized studies (fig. 5a, b). These findings
are confirmed by pathological findings in the human pros-
tate demonstrating that individual lesions became bigger
with higher temperature and higher initial power [35]
which was known already from animal experiments [14,
25]. Convincing clinical results were also achieved using a
Nd:YAG laser with a 1-min treatment cycle with an ini-
tial power of 50 W, accompanied by a marked reduction
of treatment time [14].
When the symptomatic outcome is compared in the
same studies [12, 36, 59–61], the difference between the
different laser power is rather small (fig. 5c). At the first
look, this is a surprise, but can be seen as another proof of
the well-known fact that there is no correlation of symp-
toms, bladder outlet obstruction and prostate volume and
that symptomatic relief, even if comparable to TURP in a
randomized study, does not automatically serve as proof
for desobstruction.
ILC is clearly suitable to debulk large prostates [13, 16,
33, 37, 38, 41–43, 47–49] and to treat highly obstructive
patients [12–14, 16, 19, 33, 34, 36–43, 47–52, 55–62].
Therefore, ILC can be seen as a true alternative to TURP
with certain advantages, such as almost no serious mor-
bidity and with certain disadvantages, such as the need
for postoperative catheterization. Furthermore, ILC can
be done in local anesthesia and does not require hospitali-
zation [34]. However, ILC also seems to be suitable as an
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alternative to treat less obstructive but symptomatic BPH
patients when performed with lower power or a smaller
number of punctures. The tissue effects of this approach
could be expected to be similar to those achieved by low-
energy transurethral microwave thermotherapy (TUMT)
or transurethral needle ablation (TUNA). Because of less
coagulation volume and less concomittant edema, the
postoperative increase of obstruction would be less and
would probably also compare to TUMT and TUNA, thus
eliminating long postoperative catheterization, although
this remains to be proven. However, the existing data sug-
gest ILC to be adaptable to treat all different types of BPH
syndrome, lower urinary tract symptoms with or without
obstruction and with or without prostate enlargement.
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